IDENIX PHARMACEUTICALS INC's ticker is IDIX and the CUSIP is 45166R204. A total of 135 filers reported holding IDENIX PHARMACEUTICALS INC in Q2 2014. The put-call ratio across all filers is 1.79 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2014 | $2,175,000 | +345.7% | 90,248 | +11.4% | 0.01% | +350.0% |
| Q1 2014 | $488,000 | +5.9% | 80,996 | +5.1% | 0.00% | 0.0% |
| Q4 2013 | $461,000 | -1.1% | 77,092 | -13.7% | 0.00% | 0.0% |
| Q3 2013 | $466,000 | +80.6% | 89,378 | +25.2% | 0.00% | +100.0% |
| Q2 2013 | $258,000 | – | 71,385 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Baupost Group | 53,331,109 | $1,269,560,000 | 20.68% |
| Sarissa Capital Management LP | 2,000,000 | $48,200,000 | 16.39% |
| GLAZER CAPITAL, LLC | 981,058 | $23,643,000 | 9.35% |
| 12 West Capital Management LP | 1,431,480 | $34,499,000 | 4.42% |
| HAVENS ADVISORS LLC | 251,000 | $6,049,000 | 4.39% |
| GABELLI & Co INVESTMENT ADVISERS, INC. | 584,480 | $14,086,000 | 3.04% |
| LONGFELLOW INVESTMENT MANAGEMENT CO LLC | 500,000 | $12,050,000 | 2.26% |
| Bain Capital Public Equity Management, LLC | 3,364,623 | $81,087,000 | 1.96% |
| ANGELO GORDON & CO., L.P. | 1,000,000 | $24,100,000 | 1.88% |
| FIRST NEW YORK SECURITIES LLC /NY | 586 | $1,069,660,000 | 1.10% |